Tanios S. Bekaii-Saab, MD, on Next-Generation Sequencing for Gastrointestinal Cancer

Video

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Next-generation sequencing has revolutionized genomic research, helping oncologists to deliver the proper treatment to the proper target, thereby improving outcomes.

Specifically for patients with gastrointestinal cancers, precision therapy has represented a paradigm shift in the way oncologists approach patient care.

In an interview with CancerNetwork®, Tanios S. Bekaii-Saab, MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed why next-generation sequencing is so important for patients with gastrointestinal cancers, as well as the need to make genomic sequencing the standard of care for this entire patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Related Content